Review



human il2 mab  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems human il2 mab
    Sustained <t>IL2</t> stimulation is responsible for the adjuvant effect of IL2Cx. A, TgTR1 cells were incubated with Trp1 peptide (1 µg/ml) and IL2Cx122 or IL2Cx25 (100 ng IL2/ml) in the presence of increasing concentrations of homologue IL2 mAb (JES6-5H4 or JES6-1A12, respectively). Seven days later T-cell expansion was evaluated. B, CD45.1 mice were adoptively transferred with 1 × 105 TgTR1 cells followed by BiVax prime. Five days later the mice were boosted with BiVax, BiVax/IL2Cx25(10 µg) (2 µg IL2 + 10 µg IL2 mAb) or BiVax/IL2Cx25(300 µg) (2 µg IL2 + 300 µg IL2 mAb). On day 12 the total numbers of TgTR1 cells were evaluated in spleens. C, Representative flow dot plots from the experiment in panel B, showing the percentage of TgTR1 cells (MHCII-CD45.2+) in spleen gating in total live cells. (n = 3 mice/group). Representative results are shown from at least 3 independent experiments.
    Human Il2 Mab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 58 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human il2 mab/product/R&D Systems
    Average 94 stars, based on 58 article reviews
    human il2 mab - by Bioz Stars, 2026-05
    94/100 stars

    Images

    1) Product Images from "Sustained persistence of IL2 signaling enhances the antitumor effect of peptide vaccines through T-cell expansion and preventing PD-1 inhibition"

    Article Title: Sustained persistence of IL2 signaling enhances the antitumor effect of peptide vaccines through T-cell expansion and preventing PD-1 inhibition

    Journal: Cancer immunology research

    doi: 10.1158/2326-6066.CIR-17-0549

    Sustained IL2 stimulation is responsible for the adjuvant effect of IL2Cx. A, TgTR1 cells were incubated with Trp1 peptide (1 µg/ml) and IL2Cx122 or IL2Cx25 (100 ng IL2/ml) in the presence of increasing concentrations of homologue IL2 mAb (JES6-5H4 or JES6-1A12, respectively). Seven days later T-cell expansion was evaluated. B, CD45.1 mice were adoptively transferred with 1 × 105 TgTR1 cells followed by BiVax prime. Five days later the mice were boosted with BiVax, BiVax/IL2Cx25(10 µg) (2 µg IL2 + 10 µg IL2 mAb) or BiVax/IL2Cx25(300 µg) (2 µg IL2 + 300 µg IL2 mAb). On day 12 the total numbers of TgTR1 cells were evaluated in spleens. C, Representative flow dot plots from the experiment in panel B, showing the percentage of TgTR1 cells (MHCII-CD45.2+) in spleen gating in total live cells. (n = 3 mice/group). Representative results are shown from at least 3 independent experiments.
    Figure Legend Snippet: Sustained IL2 stimulation is responsible for the adjuvant effect of IL2Cx. A, TgTR1 cells were incubated with Trp1 peptide (1 µg/ml) and IL2Cx122 or IL2Cx25 (100 ng IL2/ml) in the presence of increasing concentrations of homologue IL2 mAb (JES6-5H4 or JES6-1A12, respectively). Seven days later T-cell expansion was evaluated. B, CD45.1 mice were adoptively transferred with 1 × 105 TgTR1 cells followed by BiVax prime. Five days later the mice were boosted with BiVax, BiVax/IL2Cx25(10 µg) (2 µg IL2 + 10 µg IL2 mAb) or BiVax/IL2Cx25(300 µg) (2 µg IL2 + 300 µg IL2 mAb). On day 12 the total numbers of TgTR1 cells were evaluated in spleens. C, Representative flow dot plots from the experiment in panel B, showing the percentage of TgTR1 cells (MHCII-CD45.2+) in spleen gating in total live cells. (n = 3 mice/group). Representative results are shown from at least 3 independent experiments.

    Techniques Used: Adjuvant, Incubation

    PEG-IL2 is effective in expanding BiVax generated antigen-specific T cells. A, WT mice (3/group) were vaccinated with BiVax prime. Five days later the mice received boosters with BiVax, BiVax/IL2, BiVax/IL2Cx122 or BiVax/PEG-IL2. Seven days later the numbers of Trp1 tetramer+ T cells were evaluated in spleens. B, WT mice were inoculated s.c. with B16F10 cells and 7 days later, received a BiVax prime followed 5 days later by booster vaccines with BiVax, BiVax/IL2 or BiVax/PEG-IL2. Tumor size growth curves showing means with SD for each group. (n = 10 mice/group). C, purified CD8+ T cells from WT mice receiving BiVax prime-boost (5 days apart) and treated or not with PEG-IL2 were incubated with either B16F10 (PD-L1 low) cells, IFNγ-treated (PD-L1 high) B16F10 cells (pulsed with 1 µg Trp1) with or without PD-L1 mAb (10 µg/ml) and the numbers of IFNγ-producing cells were evaluated by EliSpot. Representative results are shown from at least 3 independent experiments.
    Figure Legend Snippet: PEG-IL2 is effective in expanding BiVax generated antigen-specific T cells. A, WT mice (3/group) were vaccinated with BiVax prime. Five days later the mice received boosters with BiVax, BiVax/IL2, BiVax/IL2Cx122 or BiVax/PEG-IL2. Seven days later the numbers of Trp1 tetramer+ T cells were evaluated in spleens. B, WT mice were inoculated s.c. with B16F10 cells and 7 days later, received a BiVax prime followed 5 days later by booster vaccines with BiVax, BiVax/IL2 or BiVax/PEG-IL2. Tumor size growth curves showing means with SD for each group. (n = 10 mice/group). C, purified CD8+ T cells from WT mice receiving BiVax prime-boost (5 days apart) and treated or not with PEG-IL2 were incubated with either B16F10 (PD-L1 low) cells, IFNγ-treated (PD-L1 high) B16F10 cells (pulsed with 1 µg Trp1) with or without PD-L1 mAb (10 µg/ml) and the numbers of IFNγ-producing cells were evaluated by EliSpot. Representative results are shown from at least 3 independent experiments.

    Techniques Used: Generated, Vaccines, Purification, Incubation, Enzyme-linked Immunospot



    Similar Products

    human/primate il-2 antibody  (Bio-Techne corporation)
    94
    Bio-Techne corporation human/primate il-2 antibody
    Human/Primate Il 2 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human/primate il-2 antibody/product/Bio-Techne corporation
    Average 94 stars, based on 1 article reviews
    human/primate il-2 antibody - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    anti-human il2 mab mq1-17h12) conjugated apc  (Becton Dickinson)
    90
    Becton Dickinson anti-human il2 mab mq1-17h12) conjugated apc
    Anti Human Il2 Mab Mq1 17h12) Conjugated Apc, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-human il2 mab mq1-17h12) conjugated apc/product/Becton Dickinson
    Average 90 stars, based on 1 article reviews
    anti-human il2 mab mq1-17h12) conjugated apc - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    human il2 mab  (R&D Systems)
    94
    R&D Systems human il2 mab
    Sustained <t>IL2</t> stimulation is responsible for the adjuvant effect of IL2Cx. A, TgTR1 cells were incubated with Trp1 peptide (1 µg/ml) and IL2Cx122 or IL2Cx25 (100 ng IL2/ml) in the presence of increasing concentrations of homologue IL2 mAb (JES6-5H4 or JES6-1A12, respectively). Seven days later T-cell expansion was evaluated. B, CD45.1 mice were adoptively transferred with 1 × 105 TgTR1 cells followed by BiVax prime. Five days later the mice were boosted with BiVax, BiVax/IL2Cx25(10 µg) (2 µg IL2 + 10 µg IL2 mAb) or BiVax/IL2Cx25(300 µg) (2 µg IL2 + 300 µg IL2 mAb). On day 12 the total numbers of TgTR1 cells were evaluated in spleens. C, Representative flow dot plots from the experiment in panel B, showing the percentage of TgTR1 cells (MHCII-CD45.2+) in spleen gating in total live cells. (n = 3 mice/group). Representative results are shown from at least 3 independent experiments.
    Human Il2 Mab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human il2 mab/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    human il2 mab - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    fluorescein isothiocyanate (fitc)-conjugated mab human il2  (Becton Dickinson)
    90
    Becton Dickinson fluorescein isothiocyanate (fitc)-conjugated mab human il2
    Sustained <t>IL2</t> stimulation is responsible for the adjuvant effect of IL2Cx. A, TgTR1 cells were incubated with Trp1 peptide (1 µg/ml) and IL2Cx122 or IL2Cx25 (100 ng IL2/ml) in the presence of increasing concentrations of homologue IL2 mAb (JES6-5H4 or JES6-1A12, respectively). Seven days later T-cell expansion was evaluated. B, CD45.1 mice were adoptively transferred with 1 × 105 TgTR1 cells followed by BiVax prime. Five days later the mice were boosted with BiVax, BiVax/IL2Cx25(10 µg) (2 µg IL2 + 10 µg IL2 mAb) or BiVax/IL2Cx25(300 µg) (2 µg IL2 + 300 µg IL2 mAb). On day 12 the total numbers of TgTR1 cells were evaluated in spleens. C, Representative flow dot plots from the experiment in panel B, showing the percentage of TgTR1 cells (MHCII-CD45.2+) in spleen gating in total live cells. (n = 3 mice/group). Representative results are shown from at least 3 independent experiments.
    Fluorescein Isothiocyanate (Fitc) Conjugated Mab Human Il2, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fluorescein isothiocyanate (fitc)-conjugated mab human il2/product/Becton Dickinson
    Average 90 stars, based on 1 article reviews
    fluorescein isothiocyanate (fitc)-conjugated mab human il2 - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    anti human il2 mab  (R&D Systems)
    94
    R&D Systems anti human il2 mab
    Sustained <t>IL2</t> stimulation is responsible for the adjuvant effect of IL2Cx. A, TgTR1 cells were incubated with Trp1 peptide (1 µg/ml) and IL2Cx122 or IL2Cx25 (100 ng IL2/ml) in the presence of increasing concentrations of homologue IL2 mAb (JES6-5H4 or JES6-1A12, respectively). Seven days later T-cell expansion was evaluated. B, CD45.1 mice were adoptively transferred with 1 × 105 TgTR1 cells followed by BiVax prime. Five days later the mice were boosted with BiVax, BiVax/IL2Cx25(10 µg) (2 µg IL2 + 10 µg IL2 mAb) or BiVax/IL2Cx25(300 µg) (2 µg IL2 + 300 µg IL2 mAb). On day 12 the total numbers of TgTR1 cells were evaluated in spleens. C, Representative flow dot plots from the experiment in panel B, showing the percentage of TgTR1 cells (MHCII-CD45.2+) in spleen gating in total live cells. (n = 3 mice/group). Representative results are shown from at least 3 independent experiments.
    Anti Human Il2 Mab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti human il2 mab/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    anti human il2 mab - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Sustained IL2 stimulation is responsible for the adjuvant effect of IL2Cx. A, TgTR1 cells were incubated with Trp1 peptide (1 µg/ml) and IL2Cx122 or IL2Cx25 (100 ng IL2/ml) in the presence of increasing concentrations of homologue IL2 mAb (JES6-5H4 or JES6-1A12, respectively). Seven days later T-cell expansion was evaluated. B, CD45.1 mice were adoptively transferred with 1 × 105 TgTR1 cells followed by BiVax prime. Five days later the mice were boosted with BiVax, BiVax/IL2Cx25(10 µg) (2 µg IL2 + 10 µg IL2 mAb) or BiVax/IL2Cx25(300 µg) (2 µg IL2 + 300 µg IL2 mAb). On day 12 the total numbers of TgTR1 cells were evaluated in spleens. C, Representative flow dot plots from the experiment in panel B, showing the percentage of TgTR1 cells (MHCII-CD45.2+) in spleen gating in total live cells. (n = 3 mice/group). Representative results are shown from at least 3 independent experiments.

    Journal: Cancer immunology research

    Article Title: Sustained persistence of IL2 signaling enhances the antitumor effect of peptide vaccines through T-cell expansion and preventing PD-1 inhibition

    doi: 10.1158/2326-6066.CIR-17-0549

    Figure Lengend Snippet: Sustained IL2 stimulation is responsible for the adjuvant effect of IL2Cx. A, TgTR1 cells were incubated with Trp1 peptide (1 µg/ml) and IL2Cx122 or IL2Cx25 (100 ng IL2/ml) in the presence of increasing concentrations of homologue IL2 mAb (JES6-5H4 or JES6-1A12, respectively). Seven days later T-cell expansion was evaluated. B, CD45.1 mice were adoptively transferred with 1 × 105 TgTR1 cells followed by BiVax prime. Five days later the mice were boosted with BiVax, BiVax/IL2Cx25(10 µg) (2 µg IL2 + 10 µg IL2 mAb) or BiVax/IL2Cx25(300 µg) (2 µg IL2 + 300 µg IL2 mAb). On day 12 the total numbers of TgTR1 cells were evaluated in spleens. C, Representative flow dot plots from the experiment in panel B, showing the percentage of TgTR1 cells (MHCII-CD45.2+) in spleen gating in total live cells. (n = 3 mice/group). Representative results are shown from at least 3 independent experiments.

    Article Snippet: IL2Cx were administered i.p. Human IL2Cx (huIL2Cx) was made from recombinant human IL2 (2 μg/mouse, Peprotech, cat. # 200-02) and human IL2 mAb (10 μg/ml, R&D Systems, cat. # MAB602).

    Techniques: Adjuvant, Incubation

    PEG-IL2 is effective in expanding BiVax generated antigen-specific T cells. A, WT mice (3/group) were vaccinated with BiVax prime. Five days later the mice received boosters with BiVax, BiVax/IL2, BiVax/IL2Cx122 or BiVax/PEG-IL2. Seven days later the numbers of Trp1 tetramer+ T cells were evaluated in spleens. B, WT mice were inoculated s.c. with B16F10 cells and 7 days later, received a BiVax prime followed 5 days later by booster vaccines with BiVax, BiVax/IL2 or BiVax/PEG-IL2. Tumor size growth curves showing means with SD for each group. (n = 10 mice/group). C, purified CD8+ T cells from WT mice receiving BiVax prime-boost (5 days apart) and treated or not with PEG-IL2 were incubated with either B16F10 (PD-L1 low) cells, IFNγ-treated (PD-L1 high) B16F10 cells (pulsed with 1 µg Trp1) with or without PD-L1 mAb (10 µg/ml) and the numbers of IFNγ-producing cells were evaluated by EliSpot. Representative results are shown from at least 3 independent experiments.

    Journal: Cancer immunology research

    Article Title: Sustained persistence of IL2 signaling enhances the antitumor effect of peptide vaccines through T-cell expansion and preventing PD-1 inhibition

    doi: 10.1158/2326-6066.CIR-17-0549

    Figure Lengend Snippet: PEG-IL2 is effective in expanding BiVax generated antigen-specific T cells. A, WT mice (3/group) were vaccinated with BiVax prime. Five days later the mice received boosters with BiVax, BiVax/IL2, BiVax/IL2Cx122 or BiVax/PEG-IL2. Seven days later the numbers of Trp1 tetramer+ T cells were evaluated in spleens. B, WT mice were inoculated s.c. with B16F10 cells and 7 days later, received a BiVax prime followed 5 days later by booster vaccines with BiVax, BiVax/IL2 or BiVax/PEG-IL2. Tumor size growth curves showing means with SD for each group. (n = 10 mice/group). C, purified CD8+ T cells from WT mice receiving BiVax prime-boost (5 days apart) and treated or not with PEG-IL2 were incubated with either B16F10 (PD-L1 low) cells, IFNγ-treated (PD-L1 high) B16F10 cells (pulsed with 1 µg Trp1) with or without PD-L1 mAb (10 µg/ml) and the numbers of IFNγ-producing cells were evaluated by EliSpot. Representative results are shown from at least 3 independent experiments.

    Article Snippet: IL2Cx were administered i.p. Human IL2Cx (huIL2Cx) was made from recombinant human IL2 (2 μg/mouse, Peprotech, cat. # 200-02) and human IL2 mAb (10 μg/ml, R&D Systems, cat. # MAB602).

    Techniques: Generated, Vaccines, Purification, Incubation, Enzyme-linked Immunospot